AbbVie Inc. et al v. Alkem Laboratories Limited et al
| AbbVie Inc., AbbVie Ltd. and Neurocrine Biosciences, Inc. |
| Alkem Laboratories Limited, Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lupin Limited, Lupin Pharmaceuticals Inc., MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc., Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Solco Healthcare US, LLC, Sandoz Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Zenara Pharma Private Limited and Biophore India Pharmaceuticals Private Ltd. |
| 1:2022cv01423 |
| October 27, 2022 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Jennifer L Hall |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on April 27, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 96 NOTICE OF SERVICE of Plaintiffs' Disclosures to Zenara Defendants Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 95 NOTICE OF SERVICE of Plaintiffs' Disclosures to Defendant Teva Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 94 NOTICE OF SERVICE of Plaintiffs' Disclosures to Defendant Sun Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 93 NOTICE OF SERVICE of Plaintiffs' Disclosures to Defendant Sandoz Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 92 NOTICE OF SERVICE of Plaintiffs' Disclosures to Prinston Defendants Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 91 NOTICE OF SERVICE of Plaintiffs' Disclosures to MSN Defendants Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 90 NOTICE OF SERVICE of Plaintiffs' Disclosures to Lupin Defendants Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 89 NOTICE OF SERVICE of Plaintiffs' Disclosures to Hetero Defendants Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 88 NOTICE OF SERVICE of Plaintiffs' Disclosures to Defendant Alkem Pursuant to Paragraph 4(a) of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
SO ORDERED, re #87 STIPULATION and Proposed Order to extend time to file a proposed protective order to May 1, 2023. Signed by Judge Richard G. Andrews on 4/25/2023. (nms)
|
| Filing 87 STIPULATION and Proposed Order to extend time to file a proposed protective order to May 1, 2023 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 4/25/2023 (nms). |
| Filing 86 NOTICE OF SERVICE of (1) Defendants Lupin Limited and Lupin Pharmaceuticals, Inc's Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Plaintiffs; and (2) Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.'s Initial Disclosures Pursuant to Paragraph 3 of the District of Delaware's Default Standard for Discovery to Plaintiffs filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
| Filing 85 NOTICE OF SERVICE of MSN Defendants' Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1); and 2) MSN Defendants' Initial Disclosures Pursuant to Paragraph (3)(b)-(c) of the Default Standard for Discovery filed by MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc..(Wilson, Samantha) |
| Filing 84 NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., and Solco Healthcare US, LLC's Fed. R. Civ. P. 26(a)(1)(A) Initial Disclosures and Paragraph 3 Disclosures filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Taylor, Daniel) |
| Filing 83 NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Zenara Defendants and (2) Plaintiffs' Initial Disclosures to Zenara Defendants Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 82 NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Teva Defendant and (2) Plaintiffs' Initial Disclosures to Teva Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 81 NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Sun Defendant and (2) Plaintiffs' Initial Disclosures to Sun Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 80 NOTICE OF SERVICE of (i) Defendant Sandoz Inc.'s Disclosures Pursuant to Paragraph 3 of the District of Delaware Default Standard for Discovery; and, (ii) Defendant Sandoz Inc.'s Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Sandoz Inc..(Gattuso, Dominick) |
| Filing 79 NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Sandoz Defendant and (2) Plaintiffs' Initial Disclosures to Sandoz Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 78 NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Prinston Defendants and (2) Plaintiffs' Initial Disclosures to Prinston Defendants Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 77 NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to MSN Defendants and (2) Plaintiffs' Initial Disclosures to MSN Defendants Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 76 NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Lupin Defendants and (2) Plaintiffs' Initial Disclosures to Lupin Defendants Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 75 NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Hetero Defendants and (2) Plaintiffs' Initial Disclosures to Hetero Defendants Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 74 NOTICE OF SERVICE of (1) Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures to Alkem Defendant and (2) Plaintiffs' Initial Disclosures to Alkem Pursuant to Paragraph 3 of the Default Standard for Discovery filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) |
| Filing 73 NOTICE OF SERVICE of Initial Disclosures filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Grivner, Geoffrey) |
| Filing 72 NOTICE OF SERVICE of 1. Defendant Teva Pharmaceuticals, Inc.'s Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery 2. Defendant Teva Pharmaceuticals, Inc.'s Rule 26(a)(1) Initial Disclosures filed by Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) |
| Filing 71 NOTICE OF SERVICE of Defendants Zenara Pharma Private Ltd. and Biophore India Pharmaceuticals Private Ltd.'s Fed. R. Civ. P. 26(a)(1)(A) Initial Disclosures & Paragraph 3 Disclosures filed by Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited.(Taylor, Daniel) |
| Filing 70 NOTICE OF SERVICE of Defendant Alkem Laboratories Limited's Fed. R. Civ. P. 26(a)(1)(A) Initial Disclosures & Paragraph 3 Disclosures filed by Alkem Laboratories Limited.(Taylor, Daniel) |
| Filing 69 NOTICE OF SERVICE of 1) Sun Pharmaceutical Industries Ltd.'s Initial Disclosures Under Rule 26(a)(1), and 2) Sun Pharmaceutical Industries Ltd.'s Initial Disclosures Under Paragraph 3 of the Default Standard for Discovery filed by Sun Pharmaceutical Industries Limited.(Wilson, Samantha) |
| Filing 68 NOTICE of Appearance by Daniel Taylor on behalf of Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zenara Pharma Private Limited, Zhejiang Huahai Pharmaceutical Co., Ltd. (Taylor, Daniel) |
| Pro Hac Vice Attorney Christopher W. West for Lupin Limited and Lupin Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Pro Hac Vice Attorney Mitchell R. Williams for Sun Pharmaceutical Industries Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Filing 67 MOTION for Pro Hac Vice Appearance of Attorney Christopher W. West - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) |
|
Filing 66
ORAL ORDER: The Motion for Pro Hac Vice Appearance (D.I. #65 ) is DISMISSED without prejudice to renew. Certifications by counsel need to be dated as to the day they were signed. Ordered by Judge Richard G. Andrews on 4/13/2023. (nms)
|
| Filing 65 MOTION for Pro Hac Vice Appearance of Attorney Christopher W. West - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) |
|
SO ORDERED, re #67 MOTION for Pro Hac Vice Appearance of Attorney Christopher W. West, filed by Lupin Pharmaceuticals Inc., Lupin Limited. Signed by Judge Richard G. Andrews on 4/13/2023. (nms)
|
| Filing 64 MOTION for Pro Hac Vice Appearance of Attorney Mitchell R. Williams - filed by Sun Pharmaceutical Industries Limited. (Wilson, Samantha) |
|
SO ORDERED, re #64 MOTION for Pro Hac Vice Appearance of Attorney Mitchell R. Williams, filed by Sun Pharmaceutical Industries Limited. Signed by Judge Richard G. Andrews on 4/12/2023. (nms)
|
|
Filing 63
ORAL ORDER: A Motion for Teleconference to Resolve Discovery Dispute should be filed if counsel finds they are unable to resolve a discovery matter. The suggested text for this motion can be found in Judge Hall's portion of the Court's website, in the "Forms" tab, under the heading "Motion for Teleconference to Resolve Discovery/Protective Order Disputes." The dispute will thereafter be addressed in accordance with Judge Hall's discovery dispute procedures. Ordered by Judge Jennifer L. Hall on 3/21/2023. (ceg)
|
|
Filing 62
ORAL ORDER: The Rule 16(b) Conference scheduled for 3/23/2023, is CANCELED. Ordered by Judge Richard G. Andrews on 3/21/2023. (nms)
|
|
Filing 61
SCHEDULING ORDER: This matter will be referred to a magistrate judge to handle all discovery disputes including any that arise in connection with expert reports. Joinder of Parties due by 4/11/2024. Amended Pleadings due by 4/11/2024. Fact Discovery completed by 9/19/2024. Joint Claim Construction Brief due by 5/2/2024. A Markman Hearing is set for 6/3/2024, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 6/6/2025, at 9:00 AM in Courtroom 6A. A 3 day Bench Trial is set for 6/16/2025, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 3/21/2023. (nms)
|
| Filing 60 PROPOSED Scheduling Order, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Attachments: #1 Letter)(Tigan, Jeremy) Modified on 3/21/2023 (nms). |
| CASE REFERRED to Magistrate Judge Jennifer L. Hall to handle all discovery disputes including any that arise in connection with expert reports. (nms) |
| Pro Hac Vice Attorney Deirdre M. Wells for Teva Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Filing 59 MOTION for Pro Hac Vice Appearance of Attorney Deirdre M. Wells - filed by Teva Pharmaceuticals, Inc.. (Hoeschen, Nathan) |
| Filing 58 ANSWER to #50 Answer to Complaint and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 3/20/2023 (nms). |
|
SO ORDERED, re #59 MOTION for Pro Hac Vice Appearance of Attorney Deirdre M. Wells, filed by Teva Pharmaceuticals, Inc.. Signed by Judge Richard G. Andrews on 3/20/2023. (nms)
|
| Filing 57 NOTICE of Withdrawal of Appearance of Delaware Counsel, Eve Ormerod by Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zenara Pharma Private Limited, Zhejiang Huahai Pharmaceutical Co., Ltd. (Ormerod, Eve) |
| Filing 56 ANSWER to #46 Answer to Complaint, and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 3/8/2023 (nms). |
|
Filing 55
Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 3/23/2023, at 9:00 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 3/7/2023. (nms)
|
| Filing 54 ANSWER to #45 Answer to Complaint, and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 3/3/2023 (nms). |
| Filing 53 ANSWER to #44 Answer to Complaint, and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 3/3/2023 (nms). |
| Filing 52 ANSWER to #1 Complaint, with Additional Defenses, by Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited.(Belgam, Neal) Modified on 2/28/2023 (nms). |
| Pro Hac Vice Attorney Matthew V. Anderson, Kevin P. Burke, William A. Rakoczy, Adrianne C. Rose, and Kevin E. Warner for MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd. and MSN Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Filing 51 ANSWER to #43 Answer to Complaint, and Counterclaims, by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc..(Tigan, Jeremy) Modified on 2/27/2023 (nms). |
| Filing 50 ANSWER to #1 Complaint, and COUNTERCLAIMS against AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc. by Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V. (Attachments: #1 Exhibit 1, #2 Exhibit 2)(Grivner, Geoffrey) Modified on 2/27/2023 (nms). |
| Filing 49 ANSWER to #1 Complaint, and Affirmative Defenses, by Sun Pharmaceutical Industries Limited.(Gaza, Anne) Modified on 2/27/2023 (nms). |
| Filing 48 MOTION for Pro Hac Vice Appearance of Attorney William A. Rakoczy - filed by MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc.. (Wilson, Samantha) |
|
SO ORDERED, re #48 MOTION for Pro Hac Vice Appearance of Attorney William A. Rakoczy, filed by MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc.. Signed by Judge Richard G. Andrews on 2/17/2023. (nms)
|
|
SO ORDERED, re #47 MOTION for Pro Hac Vice Appearance of Attorney Kevin E. Warner, Matthew V. Anderson, Kevin P. Burke, and Adrianne C. Rose, filed by MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc.. Signed by Judge Richard G. Andrews on 2/16/2023. (nms)
|
| Filing 47 MOTION for Pro Hac Vice Appearance of Attorney Kevin E. Warner, Matthew V. Anderson, Kevin P. Burke, and Adrianne C. Rose - filed by MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc.. (Gaza, Anne) |
| Filing 46 ANSWER to #1 Complaint, and COUNTERCLAIMS against all Plaintiffs, by MSN Pharmaceuticals Inc., MSN Life Sciences Pvt. Ltd., MSN Laboratories Private Ltd..(Gaza, Anne) Modified on 2/16/2023 (nms). |
| Filing 45 ANSWER to #1 Complaint, , COUNTERCLAIM against All Plaintiffs by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James) |
| Filing 44 ANSWER to #1 Complaint, and COUNTERCLAIMS against AbbVie Inc., AbbVie Ltd., by Teva Pharmaceuticals, Inc..(DiBenedetto, Emily) Modified on 2/13/2023 (nms). |
| Pro Hac Vice Attorney Linnea P. Cipriano for Sandoz Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Pro Hac Vice Attorney Joshua S. Weinger for Sandoz Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Pro Hac Vice Attorney Kelly Grosshuesch for Sandoz Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Pro Hac Vice Attorney Louis L. Lobel for Sandoz Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Filing 43 ANSWER to #1 Complaint, and COUNTERCLAIMS against all Plaintiffs, by Sandoz Inc..(Gattuso, Dominick) Modified on 2/7/2023 (nms). |
| Pro Hac Vice Attorney Cristina Denise Go for Sandoz Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Filing 42 MOTION for Pro Hac Vice Appearance of Attorney Emily L. Rapalino, Linnea P. Cipriano, Joshua S. Weinger, Louis L. Lobel, Kelly Grosshuesch and Cristina Denise Go of Goodwin Procter LLP - filed by Sandoz Inc.. (Gattuso, Dominick) |
|
SO ORDERED, re #42 MOTION for Pro Hac Vice Appearance of Attorney Emily L. Rapalino, Linnea P. Cipriano, Joshua S. Weinger, Louis L. Lobel, Kelly Grosshuesch and Cristina Denise Go of Goodwin Procter LLP, filed by Sandoz Inc.. Signed by Judge Richard G. Andrews on 2/1/2023. (nms)
|
| Pro Hac Vice Attorney Jillian M. Schurr for Lupin Limited and Lupin Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Filing 41 Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals, Inc. filed by Teva Pharmaceuticals, Inc.. (DiBenedetto, Emily) |
| Filing 40 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Biophore India Pharmaceuticals Private Ltd. for Zenara Pharma Private Limited filed by Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited. (Belgam, Neal) |
| Filing 39 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Alkem Laboratories Limited. (Belgam, Neal) |
| Pro Hac Vice Attorney Dmitry V. Shelhoff, Edward D. Pergament, Julia S. Kim, and Kenneth S. Canfield for Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., and Zenara Pharma Private Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr) |
| Pro Hac Vice Attorney Lance A. Soderstrom for Lupin Limited and Lupin Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Filing 38 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent MSN Laboratories Private Ltd. for MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc. filed by MSN Laboratories Private Ltd., MSN Life Sciences Pvt. Ltd., MSN Pharmaceuticals Inc.. (Gaza, Anne) |
| Filing 37 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Sun Pharmaceutical Industries Limited. (Gaza, Anne) |
| Filing 36 MOTION for Pro Hac Vice Appearance of Attorney Deepro R. Mukerjee, Lance A. Soderstrom, and Jillian M. Schurr - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) |
| Filing 35 MOTION for Pro Hac Vice Appearance of Attorney Dmitry V. Shelhoff, Edward D. Pergament, Kenneth S. Canfield and Julia S. Kim - filed by Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited. (Belgam, Neal) |
| Filing 34 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Inc. for Lupin Pharmaceuticals Inc. filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) |
|
SO ORDERED, re #36 MOTION for Pro Hac Vice Appearance of Attorney Deepro R. Mukerjee, Lance A. Soderstrom, and Jillian M. Schurr, filed by Lupin Pharmaceuticals Inc., Lupin Limited. Signed by Judge Richard G. Andrews on 1/19/2023. (nms)
|
|
SO ORDERED, re #35 MOTION for Pro Hac Vice Appearance of Attorney Dmitry V. Shelhoff, Edward D. Pergament, Kenneth S. Canfield and Julia S. Kim, filed by Alkem Laboratories Limited, Biophore India Pharmaceuticals Private Ltd., Zenara Pharma Private Limited. Signed by Judge Richard G. Andrews on 1/19/2023. (nms)
|
| Filing 33 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Sandoz Inc. filed by Sandoz Inc.. (Gattuso, Dominick) |
| Filing 32 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Hetero Drugs Limited, Corporate Parent Hetero Labs Limited for Hetero USA Inc. filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Grivner, Geoffrey) |
| Filing 31 MOTION for Pro Hac Vice Appearance of Attorney Matthew Fedowitz, Andrew Cheslock and Grant Shackelford - filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Attachments: #1 Certification of Andrew R. Cheslock, #2 Certification of Grant Shackelford, #3 Certification of Matthew Fedowitz, #4 Text of Proposed Order)(Grivner, Geoffrey) |
|
SO ORDERED, re #31 MOTION for Pro Hac Vice Appearance of Attorney Matthew Fedowitz, Andrew Cheslock and Grant Shackelford, filed by Hetero Labs Limited Unit-V, Hetero USA Inc., Hetero Labs Limited. Signed by Judge Richard G. Andrews on 1/18/2023. (nms)
|
| DEFICIENCY NOTICE issued by the Court to defendants Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lupin Limited, Lupin Pharmaceuticals Inc., Sandoz Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals, Inc.: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel for defendants are requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (nms) |
| Filing 30 MOTION for Pro Hac Vice Appearance of Attorney H. Howard Wang & Jason A. Lief - filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd.. (Ormerod, Eve) |
|
SO ORDERED, re #30 MOTION for Pro Hac Vice Appearance of Attorney H. Howard Wang & Jason A. Lief, filed by Zhejiang Huahai Pharmaceutical Co., Ltd., Solco Healthcare US, LLC, Prinston Pharmaceutical Inc.. Signed by Judge Richard G. Andrews on 1/17/2023. (nms)
|
| Pro Hac Vice Attorney H. Howard Wang and Jason A. Lief for Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, and Zhejiang Huahai Pharmaceutical Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
|
SO ORDERED, re #27 STIPULATION and Proposed Order (*Reset Answer Deadlines: MSN Laboratories Private Ltd. answer due 2/15/2023; MSN Life Sciences Pvt. Ltd. answer due 2/15/2023; MSN Pharmaceuticals Inc. answer due 2/15/2023). Signed by Judge Richard G. Andrews on 1/6/2023. (nms)
|
| Filing 29 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Zhejiang Huahai Pharmaceutical Co., Ltd. for Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd. filed by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd.. (Belgam, Neal) |
| Filing 28 ANSWER to #1 Complaint, with Additional Defenses, by Prinston Pharmaceutical Inc., Solco Healthcare US, LLC, Zhejiang Huahai Pharmaceutical Co., Ltd..(Ormerod, Eve) Modified on 1/5/2023 (nms). |
| Filing 27 STIPULATION and Proposed Order to answer, move, or otherwise respond to the Complaint to February 15, 2023 - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 1/6/2023 (nms). |
| Filing 26 STIPULATION and Proposed Order - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 1/4/2023 (nms). |
| Filing 25 STIPULATION and Proposed Order - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 1/4/2023 (nms). |
|
SO ORDERED, re #25 STIPULATION and Proposed Order (*Reset Answer Deadlines: Alkem Laboratories Limited answer due 2/28/2023). Signed by Judge Richard G. Andrews on 1/4/2023. (nms)
|
|
SO ORDERED, re #26 STIPULATION and Proposed Order (*Reset Answer Deadlines: Biophore India Pharmaceuticals Private Ltd. answer due 2/28/2023; Zenara Pharma Private Limited answer due 2/28/2023). Signed by Judge Richard G. Andrews on 1/4/2023. (nms)
|
|
Filing 24
SO ORDERED Granting #23 Stipulation and Proposed Order (*Party Teva Pharmaceutical Industries Ltd. terminated) (*Reset Answer Deadlines: Teva Pharmaceuticals, Inc. answer due 2/10/2023). Signed by Judge Richard G. Andrews on 1/3/2023. (nms)
|
| Filing 23 STIPULATION and [Proposed] Order Regarding Teva Defendants - by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) |
| Filing 22 NOTICE OF SUBSTITUTION OF COUNSEL re Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.: Entry of appearance of attorney Geoffrey Graham Grivner. Attorney Kenneth Dorsney terminated. (Grivner, Geoffrey) |
| Filing 21 STIPULATION to Extend Time to Answer, Move, or otherwise Respond to the Complaint by February 27, 2023, by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Dorsney, Kenneth) Modified on 12/21/2022 (nms). |
|
SO ORDERED, re #21 Stipulation to Extend Time (*Reset Answer Deadlines: Hetero Labs Limited answer due 2/27/2023; Hetero Labs Limited Unit-V answer due 2/27/2023; Hetero USA Inc. answer due 2/27/2023). Signed by Judge Richard G. Andrews on 12/21/2022. (nms)
|
| Filing 20 STIPULATION and Proposed Order - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 12/14/2022 (nms). |
| Filing 19 STIPULATION and Proposed Order to answer, move, or otherwise respond to the Complaint - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 12/14/2022 (nms). |
|
SO ORDERED, re #19 STIPULATION and Proposed Order (*Reset Answer Deadlines: Lupin Limited answer due 2/10/2023; Lupin Pharmaceuticals Inc. answer due 2/10/2023). Signed by Judge Richard G. Andrews on 12/14/2022. (nms)
|
|
SO ORDERED, re #20 STIPULATION and Proposed Order (*Reset Answer Deadlines: Sandoz Inc. answer due 2/6/2023). Signed by Judge Richard G. Andrews on 12/14/2022. (nms)
|
| Filing 18 STIPULATION and Proposed Order to answer, move, or otherwise respond to the Complaint - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) Modified on 12/5/2022 (nms). |
|
SO ORDERED, re #18 STIPULATION and Proposed Order to answer, move, or otherwise respond to the Complaint (*Reset Answer Deadlines: Sun Pharmaceutical Industries Limited answer due 2/27/2023). Signed by Judge Richard G. Andrews on 12/5/2022. (nms)
|
|
SO ORDERED, re #17 MOTION for Pro Hac Vice Appearance of Attorney Jennell C. Bilek and Samuel T. Lockner, filed by Sun Pharmaceutical Industries Limited. Signed by Judge Richard G. Andrews on 11/29/2022. (nms)
|
| Pro Hac Vice Attorney Jennell C. Bilek and Samuel T. Lockner for Sun Pharmaceutical Industries Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Filing 17 MOTION for Pro Hac Vice Appearance of Attorney Jennell C. Bilek and Samuel T. Lockner - filed by Sun Pharmaceutical Industries Limited. (Gaza, Anne) |
| Pro Hac Vice Attorney Constance Lee, William B. Raich, Ryan V. McDonnell, Danielle A. Duszczyszyn, and Jennifer H. Roscetti for AbbVie Inc., AbbVie Ltd., and Neurocrine Biosciences, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Filing 16 MOTION for Pro Hac Vice Appearance of Attorney Jennifer H. Roscetti, Danielle A. Duszczyszyn, William B. Raich, Constance P. Lee and Ryan V. McDonnell - filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Tigan, Jeremy) |
|
SO ORDERED, re #16 MOTION for Pro Hac Vice Appearance of Attorney Jennifer H. Roscetti, Danielle A. Duszczyszyn, William B. Raich, Constance P. Lee and Ryan V. McDonnell, filed by AbbVie Ltd., Neurocrine Biosciences, Inc., AbbVie Inc.. Signed by Judge Richard G. Andrews on 11/15/2022. (nms)
|
| Filing 15 NOTICE of Appearance by Karen Elizabeth Keller on behalf of Teva Pharmaceuticals, Inc. (Keller, Karen) |
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (nms) |
| Filing 14 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (vfm) |
| Filing 13 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AbbVie Inc. for AbbVie Ltd. filed by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (vfm) |
| Filing 12 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,056,927 B2 ;7,176,211 B2 ;7,419,983 B2 ;10,537,572 B2 ;10,682,351 B2 ;11,344,551 B2. (vfm) |
| Filing 11 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/13/2022. Date of Expiration of Patent: 09/01/2036. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) |
| Filing 10 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/29/2022. Date of Expiration of Patent: 09/01/2036. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) |
| Filing 9 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/19/2022. Date of Expiration of Patent: 09/10/2024. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) |
| Filing 8 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/30/2022. Date of Expiration of Patent: 09/10/2024. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) |
| Filing 7 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/28/2022. Date of Expiration of Patent: 09/10/2024. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) |
| Filing 6 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/15/2022. Date of Expiration of Patent: 09/10/2024. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) |
| Filing 5 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/19/2022. Date of Expiration of Patent: 09/10/2024. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) |
| Filing 4 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/13/2022. Date of Expiration of Patent: 09/10/2024. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/27/2022. Date of Expiration of Patent: 09/01/2036. SEE ATTACHED. Thirty Month Stay Deadline: 1/23/2026. (vfm) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) |
| Filing 1 COMPLAINT for Patent Infringement filed against all Defendants (Filing fee $ 402, receipt number ADEDC-3992601) - filed by AbbVie Inc., Neurocrine Biosciences, Inc., AbbVie Ltd.. (Attachments: #1 Exhibits A-F, #2 Civil Cover Sheet) (vfm) Modified on 11/2/2022 (nms). |
| No Summons Issued. (vfm) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
